BTL-785-7 for Wrinkles

Phase-Based Progress Estimates
BOYD Beauty, Birmingham, MI
BTL-785-7 - Device
Any Age
All Sexes
What conditions do you have?

Study Summary

This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive facial remodeling.

Treatment Effectiveness

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 5 months

5 months
Evaluation of skin quality and aesthetic change of the treated areas after the therapies
Evaluation of skin quality and aesthetic improvement of the treated areas after the therapies
Non-invasive facial remodeling
Subject Satisfaction
Therapy Comfort

Trial Safety

Trial Design

1 Treatment Group

Non-invasive facial remodeling
1 of 1
Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: BTL-785-7 · No Placebo Group · N/A

Non-invasive facial remodeling
Experimental Group · 1 Intervention: BTL-785-7 · Intervention Types: Device
First Studied
Drug Approval Stage
How many patients have taken this drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 months
Closest Location: BOYD Beauty · Birmingham, MI
Photo of Birmingham 1Photo of Birmingham 2Photo of Birmingham 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Wrinkles
0 CompletedClinical Trials

Who is running the clinical trial?

BTL Industries Ltd.Lead Sponsor
42 Previous Clinical Trials
1,486 Total Patients Enrolled
9 Trials studying Wrinkles
259 Patients Enrolled for Wrinkles

Eligibility Criteria

Age Any Age · null Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a healthy male or female over 21 years of age seeking treatment for facial remodeling.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.